Importantly, AR signaling is a potential therapeutic target in ER-/AR+ breast cancer and is currently under investigation in a clinical trial (ClinicalTrials.gov Identifier: NCT00468715), [12,14-16]. Here, ESR1 is linked to breast carcinoma.